AstraZeneca site offers docs live chat with reps

Share this article:
AstraZeneca site offers docs live chat with reps
AstraZeneca site offers docs live chat with reps
AstraZeneca has launched a professional site for its Vimovo arthritis drug that features a live chat option.

The site, at www.vimovotouchpoints.com, lets docs chat with AstraZeneca “account specialists,” order samples, view up to 200 live webcasts about the drug in its “Speakers Forum” series, and download discount cards for patients.

“What we're trying to do is to recognize how busy our customers are these days by ensuring that information and services for our products are available and convenient to use when they want to use it,” said Lisa Schoenberg, VP specialty care at AstraZeneca.

The platform for the site, executed by agency Digitas, will be gradually deployed across the company's product line. While elements like patient savings cards, online samples and access to prescribing and formulary info are already in place on many brand.com sites, AstraZeneca sees the more personal elements – live chats with reps, video details and educational webcasts – giving them an edge.

Schoenberg says online efforts like these won't replace in-person promotion.

“There's nothing like actually sitting down and having a conversation, even if it's in the hallway, eye-to-eye with somebody and being able to engage with your customers, answer their questions and provide them with relevant information,” said Schoenberg. But it is an acknowledgment of diminished sales forces and the increasing difficulty of getting a foot in the door at the doctor's office. “We're trying to take the best of what we've done in the past and build on it to see if we can redefine the effective launch of a pharmaceutical product in a new environment and a new time,” she said.

A combo NSAID/PPI drug (naproxen/esomeprazole magnesium), Vimovo won FDA approval in April for the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Launched late last month, Vimovo carries a boxed warning for cardiovascular and gastrointestinal risks.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...